Bergsbaken J - Search Results

1

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. Berger MJ, et al. Among authors: bergsbaken j. J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117. J Natl Compr Canc Netw. 2017. PMID: 28687576

2

Implementation of a clinical pharmacist-led service to optimize management of refractory chemotherapy-induced nausea and vomiting in adult hematology/oncology clinic.

Quinn CS, Bergsbaken JJ, Blessinger EJ, Piccolo JK. Quinn CS, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2022 Oct;28(7):1499-1507. doi: 10.1177/10781552211029702. Epub 2021 Jul 5. J Oncol Pharm Pract. 2022. PMID: 34225524

3

PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.

Hennes ER, Dow-Hillgartner EN, Bergsbaken JJ, Piccolo JK. Hennes ER, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2020 Apr;26(3):718-729. doi: 10.1177/1078155219895066. Epub 2020 Jan 6. J Oncol Pharm Pract. 2020. PMID: 31902284 Review.

4

Hypertension and QT interval prolongation associated with targeted systemic cancer therapies.

Fahey OG, Piccolo JK, Bergsbaken JJ, N Dow-Hillgartner E. Fahey OG, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2020 Dec;26(8):1987-1996. doi: 10.1177/1078155220958462. Epub 2020 Sep 21. J Oncol Pharm Pract. 2020. PMID: 32951523

5

Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?

Przybylski DJ, Bergsbaken JJ, Piccolo JK. Przybylski DJ, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2021 Jun;27(4):930-938. doi: 10.1177/1078155220984235. Epub 2021 Jan 6. J Oncol Pharm Pract. 2021. PMID: 33406979 Review.

6

Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.

Renna CE, Dow EN, Bergsbaken JJ, Leal TA. Renna CE, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2019 Jun;25(4):954-960. doi: 10.1177/1078155218817937. J Oncol Pharm Pract. 2019. PMID: 30975067

7

Automated parenteral chemotherapy dose-banding to improve patient safety and decrease drug costs.

Fahey OG, Koth SM, Bergsbaken JJ, Jones HA, Trapskin PJ. Fahey OG, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2020 Mar;26(2):345-350. doi: 10.1177/1078155219846958. Epub 2019 May 2. J Oncol Pharm Pract. 2020. PMID: 31046608

8

Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review.

Bergsbaken JJ, Eickhoff JC, Buss BA, Mably MS, Kolesar JM. Bergsbaken JJ, et al. J Oncol Pharm Pract. 2016 Feb;22(1):105-13. doi: 10.1177/1078155214567163. Epub 2015 Jan 10. J Oncol Pharm Pract. 2016. PMID: 25577495

9

Implementation of a chemotherapy stewardship process.

Hennes ER, Reed M, Mably M, Jared J, Bergsbaken JJ, Deming D, Callander N, O'Regan R. Hennes ER, et al. Among authors: bergsbaken jj. Am J Health Syst Pharm. 2020 Jul 23;77(15):1243-1248. doi: 10.1093/ajhp/zxaa157. Am J Health Syst Pharm. 2020. PMID: 32620961

10

Implementing value assessment in oncology practice: A single-center experience.

Saunders K, Mably MS, Shull SS, Jones H, Leal TA, Bergsbaken JJ. Saunders K, et al. Among authors: bergsbaken jj. J Oncol Pharm Pract. 2019 Jun;25(4):947-953. doi: 10.1177/1078155218815741. Epub 2018 Nov 27. J Oncol Pharm Pract. 2019. PMID: 30482127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page